To evaluate the effect of supplementation of vitamin K2 (menaquinone, MK-7)vs vitamin k1 on circulating levels of calcification regulators and to assess their safety in patients on regular dialysis patients.
Vascular calcification has emerged as an independent risk factor for cardiovascular morbidity and mortality, especially in chronic kidney disease . It has a predictive value of poor prognoses and clinical outcomes in CKD patients such as overall mortality and even poor arteriovenous graft maturation . Vitamin K is essential for the activation of matrix Gla protein (MGP), a powerful inhibitor of tissue calcification, functional vitamin K deficiency may contribute to high vascular calcification (VC) burden in haemodialysis patients; this is process in which mineral is pathologically deposited in blood vessels, mainly in large elastic and muscular arteries such as the aorta and the coronary, carotid, and peripheral arteries. it is Prospective, Randomized,Placebo Controlled Study
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
40
vitamin k1 tablets
vitamin k2 45 ug tablets twice daily
placebo tablets
Ainshams University
Cairo, Egypt
change in serum level of Uncarboxylated MGP
Measuring the change in serum level of Uncarboxylated MGP as a marker for calcification
Time frame: change between baseline and after 3 months
parathyroid hormone
measuring change in serum PTH
Time frame: change between baseline and after 3 months
serum calcium level
measuring the change in serum calcium level
Time frame: change between baseline and after 3 months
serum phosphate level
measuring the change in phosphate level
Time frame: change between baseline and after 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.